360 Results

People

  1. Lacouture
    Lacouture
  2. Panageas
    Panageas
  3. Wolchok
    Wolchok
  4. Motzer
    Motzer
  5. Postow
    Postow
  6. Houghton
    Houghton
  7. Zelenetz
    Zelenetz
  8. Balagula
    Balagula
  9. Livingston
    Livingston
  10. Aghajanian
    Aghajanian

Groups

  1. Department of Medicine (267)
  2. Solid Tumor Oncology Division (171)
  3. Survivorship Research (88)
  4. Division of Subspecialty Medicine (79)
  5. Hematologic Malignancies, Division of (71)
  6. Dermatology (65)
  7. Dermatology Service (63)
  8. GSK Faculty (53)
  9. Melanoma Disease Management Team (47)
  10. Melanoma and Immunotherapeutics Service (47)
  1. "pruritus"
Formats
  1. Journal Article (336)
  2. Review (15)
  3. Research Letter (3)
  4. Editorial (2)
  5. Miscellaneous (2)
  6. Conference Paper (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (267)
  2. Solid Tumor Oncology Division (171)
  3. Survivorship Research (88)
  4. Division of Subspecialty Medicine (79)
  5. Hematologic Malignancies, Division of (71)
  6. Dermatology (65)

More Groups

People
  1. Mario Lacouture (44)
  2. Jedd Wolchok (29)
  3. Katherine Panageas (16)
  4. Paul Chapman (16)
  5. Robert Motzer (14)
  6. Michael Postow (11)

More People

Years
  1. 2025 (11)
  2. 2024 (38)
  3. 2023 (28)
  4. 2022 (12)
  5. 2021 (16)
  6. 2020 (24)

More Years

Publications
  1. Lancet Oncology (30)
  2. Clinical Cancer Research (17)
  3. Journal of Clinical Oncology (17)
  4. Cancer (11)
  5. Journal of the American Academy of Dermatology (11)
  6. Annals of Oncology (9)

More Publications

Publishers
  1. Elsevier Inc. (46)
  2. Elsevier Science, Inc. (39)
  3. Springer (26)
  4. Nature Publishing Group (22)
  5. American Association for Cancer Research (20)
  6. American Society of Clinical Oncology (18)

More Publishers

Results (360)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update
    Journal Article

    Hanna, N.; Johnson, D.; Temin, S.; Baker, S. Jr; Brahmer, J.; Ellis, P. M.; Giaccone, G.; Hesketh, P. J.; Jaiyesimi, I.; Leighl, N. B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
    Journal Article

    Kim, S. B.; Dent, R.; Im, S. A.; Espié, M.; Blau, S.; Tan, A. R.; Isakoff, S. J.; Oliveira, M.; Saura, C.; Wongchenko, M. J.; more...
    Lancet Oncology (2017)

    Fulltext@MSK | Save
  • Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)
    Journal Article

    Peters, S.; Gettinger, S.; Johnson, M. L.; Jänne, P. A.; Garassino, M. C.; Christoph, D.; Toh, C. K.; Rizvi, N. A.; Chaft, J. E.; Costa, E. C.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial
    Journal Article

    Balar, A. V.; Galsky, M. D.; Rosenberg, J. E.; Powles, T.; Petrylak, D. P.; Bellmunt, J.; Loriot, Y.; Necchi, A.; Hoffman-Censits, J.; Perez-Gracia, J. L.; more...
    Lancet (2017)

    Fulltext@MSK | Save
  • D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile
    Journal Article

    Valleix, S.; Verona, G.; Jourde-Chiche, N.; Nédelec, B.; Mangione, P. P.; Bridoux, F.; Mangé, A.; Dogan, A.; Goujon, J. M.; Lhomme, M.; more...
    Nature Communications (2016)

    Fulltext@MSK | Save
  • Xerosis and pruritus as major EGFRI-associated adverse events
    Journal Article

    Clabbers, J. M. K.; Boers-Doets, C. B.; Gelderblom, H.; Stijnen, T.; Lacouture, M. E.; van der Hoeven, K. J. M.; Kaptein, A. A.
    Supportive Care in Cancer (2016)

    Fulltext@MSK | Save
  • Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial
    Journal Article

    Eggermont, A. M. M.; Chiarion-Sileni, V.; Grob, J. J.; Dummer, R.; Wolchok, J. D.; Schmidt, H.; Hamid, O.; Robert, C.; Ascierto, P. A.; Richards, J. M.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia
    Journal Article

    O'Brien, S. M.; Lamanna, N.; Kipps, T. J.; Flinn, I.; Zelenetz, A. D.; Burger, J. A.; Keating, M.; Mitra, S.; Holes, L.; Yu, A. S.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma
    Journal Article

    Johnson, D. B.; Saranga-Perry, V.; Lavin, P. J. M.; Bryan, Burnette, W.; Clark, S. W.; Uskavitch, D. R.; Wallace, D. E.; Dickson, M. A.; Kudchadkar, R. R.; Sosman, J. A.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
    Journal Article

    Naidoo, J.; Page, D. B.; Li, B. T.; Connell, L. C.; Schindler, K.; Lacouture, M. E.; Postow, M. A.; Wolchok, J. D.
    Annals of Oncology (2015)

    Fulltext@MSK | Save